Company Filing History:
Years Active: 2018-2022
Title: Innovations of Nicholas Durham
Introduction
Nicholas Durham is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting CD73. With a total of 5 patents to his name, his work has the potential to impact cancer treatment significantly.
Latest Patents
One of Nicholas Durham's latest patents is focused on binding molecules specific for CD73 and their uses. This patent provides anti-CD73 binding molecules, including antibodies and antigen-binding fragments. The disclosed compositions are designed for pharmaceutical formulations and methods aimed at diagnosing and treating diseases associated with CD73 expression, such as cancer. The treatment methods include direct therapy with the anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies with chemotherapy.
Career Highlights
Nicholas Durham is currently associated with MedImmune Limited, where he continues to innovate in the field of therapeutic development. His work is characterized by a commitment to advancing cancer treatment through targeted therapies.
Collaborations
Some of his notable coworkers include Carl Hay and Kris Sachsenmeier, who contribute to the collaborative environment at MedImmune Limited.
Conclusion
Nicholas Durham's innovative work in developing anti-CD73 binding molecules showcases his dedication to improving cancer therapies. His contributions are paving the way for new treatment options that could benefit many patients in the future.